NanoString

The companies are making three COVID-19 tools available immediately for early access, with plans to add other nCounter software and potentially develop new products.

The firm remains on track to ship its first NGS-enabled instruments, along with its new cancer transcriptome atlas panel covering more than 1,800 genes, during Q3.

Veracyte has obtained rights to a 52-gene signature developed by Yale researchers to predict disease progression in patients with idiopathic pulmonary fibrosis.

The company said its product and services revenues were about $24.5 million for the quarter, 15 percent higher than the same period last year.

The GenomeWeb Index fared better than its benchmark counterparts in March, but still fell more than 4 percent.

The company intends to use most of the proceeds to pay off debts and associated fees, and the rest to support its platform and consumables development. 

The company intends to use most of the proceeds to pay off debts and associated fees, and the rest to support its platform and consumables development.

Of the 32 firms included in the GW Index, 27 saw their stock prices drop while only five saw gains. Yet, the GW Index outperformed the Dow and Nasdaq.

The firm said it took in $33.6 million in product and service revenue in the quarter, a 42 percent increase from $23.6 million in Q4 2018.